A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Simvastatin (a Sensitive CYP3A4 Substrate) in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2019
Price : $35 *
At a glance
- Drugs Osimertinib (Primary) ; Simvastatin (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 17 Jan 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 01 Sep 2018 Results published in the British Journal of Clinical Pharmacology
- 17 Jan 2018 Planned End Date changed from 4 Jan 2018 to 31 Dec 2018.